Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Mars Petcare acquires AniCura
Mandate

Mars Petcare acquires AniCura

June 13, 2018 M&A

Vinge advises Fidelio Capital in connection with entering into an agreement with Mars Petcare regarding Mars Petcare's acquisition of AniCura.

AniCura was founded in 2011 by Fidelio Capital and The Animal Hospital Foundation in Greater Stockholm through the first merger of companion animal hospitals in the Nordic region. Since then the company grown to become one of Europe’s leading providers of high-quality veterinary care for companion animals and today AniCura has more than 4,000 veterinary professionals who provides modern, high-quality veterinary care for pets at 200 European locations across seven European countries. In 2014, Nordic Capital joined the company as a majority owner, with Fidelio Capital remaining as a significant shareholder. The acquisition is subject to customary regulatory approvals.

Vinge’s team consisted of, among others, Jonas Bergström and Joacim Rydergård.
 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025